 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) develops and commercializes minimally invasive treatment systems used in treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (“BPH”).  The Company owns two technology platforms with approximately 100 issued and pending US and international patents:   Based on these proprietary technology platforms, the Company has developed two advanced therapeutic products: the Adaptive Phased Array (APA)-1000 system for treatment of breast cancer and the Prolieve® system for the treatment of BPH. The APA-1000 uses precisely focused and controlled microwave energy to shrink breast cancer tumors without side-effects on the surrounding tissues to produce better treatment outcomes. The Company has received regulatory approvals to complete the APA 1000’s pivotal Phase-III clinical trials, the final step before marketing approval. The U.S. FDA-approved Prolieve® System is a medical device based on endo-thermotherapy that both heats the prostate and dilates the prostatic urethra. The Prolieve® System is a minimally invasive in-office treatment option for the symptoms of enlarged prostate in men.  The Prolieve® System is a revenue generating product catering to the multi billion dollar BPH market. The Company is currently focusing on marketing Prolieve® for the treatment of BPH and accelerating the APA 1000 breast cancer system’s Phase III study.

Watchers
52-Wk Low	$0.00
52-Wk High	$0.0027

Market Cap	$200.00
Volume (M)	1.63M
52-Wk High	$0.0027
52-Wk Low	$0.00

MDFZF Medifocus Inc

About

Feed

News

Fundamentals